SCHEMBL2118247

SCHEMBL2118247

COc1ccc(S(=O)(=O)Nc2cc(C)cc(-c3ccsc3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.54
FFAR4 Q5NUL3 3/20 0.54
GABRG2 P18507 1/20 0.54
GABRB3 P28472 1/20 0.54
GABRA3 P34903 1/20 0.54
CYP19A1 P11511 1/20 0.52
PKM P14618 2/20 0.52
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
MAPK1 P28482 1/20 0.49
SYK P43405 1/20 0.48
BRD4 O60885 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PLAU P00749 1/20 0.47
ALDH1A1 P00352 2/20 0.47
GHSR Q92847 1/20 0.47
MAPT P10636 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118379 0.89 IDH2 (0.50) FFAR4LMNAGAAMAPK1MEN1
SCHEMBL2119745 0.86 FFAR4 (0.64) FFAR4GABRG2GABRB3GABRA3CYP19A1
SCHEMBL2117686 0.83 FFAR4 (0.61) FFAR4GABRG2GABRB3GABRA3CYP19A1
SCHEMBL2118624 0.80 FFAR4 (0.53) FFAR4GABRG2GABRB3GABRA3CYP19A1
SCHEMBL2119453 0.80 MEN1 (0.59) FFAR4GABRG2GABRB3GABRA3CYP19A1
SCHEMBL2118375 0.78 ALPL (0.54) ALPLFFAR4GABRG2GABRB3GABRA3
SCHEMBL2118403 0.78 FFAR4 (0.54) FFAR4GABRG2GABRB3GABRA3CYP19A1
SCHEMBL2117837 0.77 STAT3 (0.60) ALPLFFAR4GABRG2GABRB3GABRA3
SCHEMBL2119862 0.77 FFAR4 (0.53) FFAR4GABRG2GABRB3GABRA3CYP19A1
SCHEMBL2120365 0.77 SYK (0.57) FFAR4GABRG2GABRB3GABRA3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 ALPL 2064/4885FFAR4 4059/4885GABRG2 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.